Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia

Leukemia and Lymphoma

Volumn 46, Issue 6, 2005, Pages 885-891

  Kim, Jong Gwang ^a   Sohn, Sang Kyun ^a   Kim, Dong Hwan ^a   Baek, Jin Ho ^a   Lee, Nan Young ^a   Suh, Jang Soo ^a   Chae, Shung Chull ^a   Lee, Kun Soo ^a   Lee, Kyu Bo ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Acute myeloid leukemia; Angiogenesis; Hepatocyte growth factor

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; CYTARABINE; GELATINASE B; IDARUBICIN; LACTATE DEHYDROGENASE; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CANCER SURVIVAL; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MONOCYTE; MULTIVARIATE ANALYSIS; ONCOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 21844444777     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500054491     Document Type: Article

References (39)

1. Diaz-Flores L, Gutierrez R, Varela H. Angiogenesis: an update. Histol Histopathol 1994;9:807-843.
2. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
3. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
4. Folkman J. Tumor angiogenesis; therapeutic implications. N Engl J Med 1971;285:1182-1186.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
6. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A:2451-2460.
7. Salvin P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90:3167.
8. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994;85:1045.
9. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995;55:510.
10. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964.
11. Aguayo A, Kantarjian H, Manshouri T et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
12. Aguayo A, O'Brien S, Keating M et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000;96:768-770.
13. Aguayo A, Estey E, Kantarjian H et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-3721.
14. Gruber G, Schwarzmeier JD, Shehata M, Hilgarth M, Berger R. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. Blood 1999;94:1077-1185.
15. Verstovsek S, Kantarjian H, Estey E et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 2001;15:1165-1170.
16. Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim JA, Turner AR, Ratajczak MZ. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002;16:1160-1166.
17. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:814-821.
18. Pruneri G, Bertolini F, Soligo D et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-1401.
19. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-19.
20. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-313.
21. Bussolino F, Di Renzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-641.
22. Glenjen N, Anders K, Bruserud Q. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patient receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer 2002;101:86-94.
23. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 2002;117:835-841.
24. Padro T, Ruiz S, Bieker R et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-2644.
25. Vacca A, Ribatti D, Presta M et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-3070.
26. Chen H, Treweeke AT, West DC et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemic cells. Blood 2000;96:3181-3187.
27. Ratajczak MZ, Ratajczak J, Machalinski B et al. Role of vascular endothelial growth factor (VEGF), placenta derived growth factor (PIGF)/Flt-1 and Flk-1/KDR receptor axes in human adult and fetal hematopoiesis. Br J Haematol 1998;103:969-979.
28. Fiedler W, Graeven U, Ergun S et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-1875.
29. Olson KA, Verselis SJ, Fett JW. Angiogenin is regulated in vivo as an acute phase protein. Biochem Biophys Res Commun 1998;242:480-483.
30. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlate with tumor progression and survival. J Clin Oncol 2001;19:577-583.
31. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999;29:209-248.
32. Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999;103:1237-1241.
33. Hjorth-Hansen H, Seidel C, Lamvik J, Borset M, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. Eur J Haematol 1999;62:129-134.
34. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998;91:806-812.
35. Borset M, Hjorth-Hansen H, Waage A, Sundan A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996;88:3998-4004.
36. Weimer IS, Voermans C, Boourhis JH et al. Hepatocyte growth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells. Leukemia 1998;12:1195-1203.
37. Beilmann M, Odenthal M, Jung W, Vande Woude GF, Dienes HP, Schirmacher P. Neo-expression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood 1997;90:4450-4458.
38. Banks RE, Forbes MA, Kinsey SE et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelet: significance for VEGF measurement and cancer biology. Br J Cancer 1998;77:956-964.
39. Molica S, Vitelli G, Levato D et al. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 2003;70:373-378.